CorFlow Therapeutics AG ("CorFlow") today announced that the company will present the Controlled Flow Infusion (CoFI™) technology for diagnosis and treatment of microvascular obstruction in patients with myocardial infarction during the upcoming PCR Innovators Day, to be held in Paris, France. Also in Paris, at EuroPCR, the company will present new preclinical findings related to intra-coronary drug infusion and how coronary artery collateral resistance and flow can be measured directly using the CoFI™ technique in the context of myocardial infarction.

The presentation during the PCR Innovators Day will be made by Prof. Javier Escaned who is the Head of the Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). Prof. Escaned is a respected interventional cardiologist with a strong track record in coronary vascular physiology and treatment options for heart attack patients.

The other posters and presentations will be made by Dr. Robert S. Schwartz, Senior Consulting Cardiologist at the Minneapolis Heart Institute (Minneapolis, MN, USA) and co-Founder of CorFlow.

Dr. Schwartz commented on this years CorFlow presentations during EuroPCR: "We are excited that the CorFlow technologies continue to open up new insights into the coronary microcirculation. This will be reflected in our presentations during the EuroPCR conference. We also appreciate that Prof. Escaned with his deep understanding of coronary physiology and coronary treatment options will present his perspectives on the CoFI™ technology during the highly regarded PCR Innovators Day."

The company will present the CoFI™ technology during three different sessions:

Monday May 20th @ 08:35 during PCR Innovators Day, Theatre Havane / level 3, during the session "Sticky problems, new solutions"
"CorFlow Therapeutics – Controlled flow infusion: a single platform for intracoronary diagnosis and treatment of microvascular obstruction in patients with AMI" presented by Prof. Javier Escaned

Tuesday May 21st to Friday May 24th @ 09:00 – 18:00 in the POSTERLAB / level 3
"Intracoronary tirofiban delivered by controlled flow infusion: marked reduction of microvascular obstruction in a porcine STEMI model" presented by Dr. Robert S. Schwartz

"Absolute coronary collateral flow and resistance during STEMI using the controlled flow infusion method" presented by Dr. Robert S. Schwartz

Tuesday May 21st @ 12:24 in the POSTERLAB / level 3 during the moderated poster session "Unanswered questions in STEMI patients", facilitated by Dr. A. Erglis and Dr. G. Gargiulo
"Intracoronary tirofiban delivered by controlled flow infusion: marked reduction of microvascular obstruction in a porcine STEMI model" presented by Dr. Robert S. Schwartz

The first poster describes studies of selective intra-coronary tirofiban delivery to the heart muscle affected by the myocardial infarction using the CorFlow CoFI™ System, and how it reduces microvascular obstruction as measured by MRI in a preclinical occlusion-reperfusion model. Even if preclinical models never can be completely representative of a human heart attack, the findings document that using a controlled method of intra-coronary tirofiban infusion has a positive effect on microvascular obstruction in the established CorFlow preclinical microvascular obstruction model.

The second poster describes how collateral coronary flow and resistance can be directly measured using the CoFI™ methods. These parameters have never been measured previously and may open novel diagnostic and therapeutic strategies. Furthermore, this technique is important to make coronary resistance calculations substantially more reliable.

Overall, the data due to be presented this month at these two important scientific meetings will contribute to consolidate the CorFlow CoFI™ technology as a solution to a major unmet need in patients with STEMI, namely the need for a dedicated diagnostic and therapeutic platform to address microvascular obstruction and, eventually, improve clinical outcomes.  

Über die CorFlow Therapeutics AG

CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as heart failure. The CorFlow technologies will enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients. 

Caution: The CorFlow Controlled Flow Infusion (CoFITM) technology is in the early phases of development. It will not be available in Europe, the US or Japan for clinical trials until further notice and is NOT available for sale. This news release contains certain “forward-looking” statements under the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CorFlow are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, European or US Food and Drug Administration (FDA) approvals of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.

Copyright © 2016 – 2018 CorFlow Therapeutics AG. All rights reserved.

Firmenkontakt und Herausgeber der Meldung:

CorFlow Therapeutics AG
Neuhofstrasse 5A
CH6340 Baar
Telefon: +41 (79) 6062-902
http://corflow-therapeutics.ch

Ansprechpartner:
Jon H. Hoem
CEO & Co-Founder
Telefon: +41 (41) 5445556
E-Mail: jhoem@corflow-therapeutics.ch
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.